Pharmacological properties of revefenacin (TD‐4208), a novel, nebulized long‐acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues

Revefenacin (TD‐4208) is a novel, long‐acting, and lung‐selective muscarinic cholinergic receptor (mAChR) antagonist in development as a nebulized inhalation solution for the treatment of chronic obstructive pulmonary disease (COPD) patients. This study evaluated the pharmacology of revefenacin at h...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacol Res Perspect
Hauptverfasser: Hegde, Sharath S., Pulido‐Rios, M. Teresa, Luttmann, Mark A., Foley, James J., Hunsberger, Gerald E., Steinfeld, Tod, Lee, TaeWeon, Ji, Yuhua, Mammen, Mathai M., Jasper, Jeffrey R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2018
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927803/
https://ncbi.nlm.nih.gov/pubmed/29736245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.400
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge